MB-106 is under clinical development by Mustang Bio and currently in Phase II for Burkitt Lymphoma. According to GlobalData, Phase II drugs for Burkitt Lymphoma have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MB-106’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MB-106 is under investigation for the treatment of refractory and relapsed B-cell non-Hodgkin lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone B-cell lymphoma, chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia, burkitt lymphoma, hairy cell leukemia and diffuse large B-cell lymphoma including primary mediastinal b-cell lymphoma. It is administered through intravenous route. The therapeutic candidate constitutes autologous T cells engineered to express chimeric antigen receptor (CAR) with anti-CD20 antibody fragment fused to signaling domains. The drug candidate is developed based on CAR-T cell technology.
Mustang Bio overview
Mustang Bio is an US based developer of cell and gene therapies for the treatment of AML and brain cancer.
For a complete picture of MB-106’s drug-specific PTSR and LoA scores, buy the report here.